An underground market for unlicensed slimming medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.
Investigational Drug Gaining Traction Via Social Media
Retatrutide, which remains in clinical trials, is being advertised by online personalities for its supposed weight-reducing properties. Viewers are encouraged to contact these accounts directly for supplier links, while also obtaining promotional offers.
Active Trade on Messaging Platforms
Additionally, a flourishing market exists on messaging services, where communities with thousands of participants share comparison images, administration instructions and claims of next-day British shipping. Vendors market the substance there before redirecting customers to other platforms for transactions.
Understanding The Experimental Drug
Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Early trials indicate it could help individuals lose up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic.
Medical Professionals Express Worries
Nevertheless, doctors and pharmacists have warned that the distribution of what remains an unlicensed medication in the UK is worrisome and could result in users injecting substances of uncertain source.
Some professionals said the popularity for the experimental drug could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.
Regulatory Position and Implementation
Selling the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Some influencers try to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and distribution can still violate pharmaceutical, marketing, and customer laws, potentially leading to penalties, prosecution or imprisonment.
Service Reaction and Material Elimination
According to TikTok, the service has removed violative content and prohibited related hashtags and search suggestions. The organization said it was dedicated to keeping the service secure and investing in enhancing enforcement strategies.
Online Marketplace Operations
Investigations also discovered groups with up to 9,000 participants selling the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, filled with photos of slimming results, positive testimonials and step-by-step instructions for mixing or administering at residence.
Within minutes of entering one community, a vendor posted WhatsApp details, where the majority of transactions take place. The seller provided an guidebook and promised shipping within two days. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed testing documentation. Not one inquired about weight, medical conditions or previous experience.
Item Details and Pricing
Inside these communities, messages display black plastic packages with postal service stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at residence with sterile water, or pre-filled injectors usually sold at 160 pounds for 20mg. When asked how long a pen should be used, sellers give conflicting answers varying between a few weeks to “depends on your body”.
Platform Oversight and Safety Measures
A spokesperson for Telegram said it regularly monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering materials they can’t verify. Although the research behind this drug is sound, these digital versions may not contain what they claim,” said a pharmacy expert, the head of pharmacy at a pharmacy service.
A medical professional of an online medical service connected the increase in interest to recent price rises for authorized weight-loss medications such as Mounjaro. “With prices rising, patients are turning to social media. But counterfeit treatments are highly risky. You cannot know what’s contained or whether the conditions they were made in was clean,” she explained.
Her staff has already seen patients harmed by personal administration from unconfirmed suppliers. “We understand the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” stated Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Statement
A spokesperson from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they said, adding that any product “falsely representing itself as a company investigational product not yet approved … may expose users to potentially serious health risks”.
